Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

Published:2021-12-22 Issue: Volume: Page:1-9
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Wong Xin Yi¹^ORCID,Chng Wee Joo²³⁴,Aziz Mohamed Ismail Abdul¹^ORCID,Ng Kwong¹

Affiliation:

1. Agency for Care Effectiveness, Ministry of Health, Singapore

2. Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore

3. Cancer Science Institute of Singapore, National University of Singapore (NUS), Singapore

4. Yong Loo Lin School of Medicine, NUS, Singapore

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.2017285

Reference37 articles.

1. Multiple Myeloma

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma

4. Minimal Residual Disease in Myeloma: Are We There Yet?

5. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models;PharmacoEconomics;2024-06-25

2. Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers;PharmacoEconomics - Open;2024-06-20

3. Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma;Cost Effectiveness and Resource Allocation;2024-02-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3